AEHA SEC filings, in plain English
Everything Aesther Healthcare Acquisition Corp. has filed with the SEC that we hold — 40 filings, newest first, 6 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“at this point in the Company’s lifecycle. These events and conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The Company”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
combination deadline, going-concern doubtnothing moved · 2 with no prior record of ours
- Combination deadline
- 2023-11-01 · unchanged
- Going-concern doubt
- stated · unchanged
The clause …“the four Initial Brown License Agreements to extend the termination dates to November 1, 2023 and to extend the termination dates of the commercialization plan of the license agreements from an additional two years to three years. For”…
The clause …“losses from operations and Ocean’s need to obtain additional capital raised substantial doubt about Ocean’s ability to continue as a going concern. Risks Related to Our Corporate Structure We may not be successful in our efforts to”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Ocean Biomedical, Inc., the post-combination successor to Aesther Healthcare Acquisition Corp., called its 2024 annual meeting for March 28, 2025 at 9:00 a.m. Mountain Time at 2511 Redwood Road, Suite 16, Woods Cross, Utah, with a record date of February 21, 2025. Why it matters: Controlled-company status means AEHA-legacy public holders have no assurance of an independent board majority or independent compensation and nominating committees — the standard protections are waived. Holding the 2024 annual meeting in March 2025, in Utah rather than at the Providence headquarters, and disclosing an Authorized Share Increase, points to a company behind on its reporting calendar and preparing to issue more stock. There is no trust or redemption right left.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“at this point in the Company’s lifecycle. These events and conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The Company”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“at this point in the Company’s lifecycle. These events and conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The Company”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
going-concern doubt, sponsor loans outstandingnothing moved · 2 with no prior record of ours
- Going-concern doubt
- stated · unchanged
- Sponsor loans outstanding
- $1.0Mnot matched in this filing
The clause …“at this point in the Company’s lifecycle. These events and conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The Company”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
- What changed vs 2023-03-31deadline 2023-03-16 → 2023-11-01
combination deadline, trust account, going-concern doubt +21 moved · 4 with no prior record of ours
- Combination deadline
- 2023-03-162023-11-01
- Trust account
- $110.4Mnot matched in this filing
- Going-concern doubt
- stated · unchanged
- Sponsor loans outstanding
- $600Knot matched in this filing
- Redeemable shares
- 10.5Mnot matched in this filing
SpacBrain reads this as 230 days later than the previous record.
The clause …“amended the Rhode Island License Agreement to extend the termination date to November 1, 2023 and to extend the termination dates of the commercialization plan of the Rhode Island License Agreement from an additional one year to three”…
The clause …“losses from operations and Ocean’s need to obtain additional capital raised substantial doubt about Ocean’s ability to continue as a going concern. Risks Related to Our Corporate Structure We may not be successful in our efforts to”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Item 3.01. On October 16, 2024 Ocean Biomedical, Inc. received a Staff Determination Letter from Nasdaq. Staff had notified it on April 18, May 22 and August 19, 2024 of non-compliance with Listing Rule 5250(c)(1) for failing to file its 2023 Form 10-K and its Forms 10-Q for the quarters ended March 31 and June 30, 2024. Based on materials submitted on June 17 and August 27, 2024, Staff had granted an exception until October 14, 2024, and determined on review that the company did not meet its terms because none of those reports was filed. The company will appeal to a Hearings Panel. Why it matters: The exception the company had been granted has lapsed with all three reports still unfiled, so this is a delisting determination rather than a deficiency notice. Only the Rule 5800 Series appeal now stands between the company and delisting. Registrant is Ocean Biomedical, recorded here under the SPAC ticker AEHA.
What changed: Item 1.01. On October 11, 2024 the board of Ocean Biomedical, Inc. unanimously ratified a revised agreement with Virion Therapeutics, originally entered in November 2023 and countersigned back to Ocean on September 26, 2024. Ocean is to receive limited liability company units bringing its holding to 22% of Virion's fully diluted membership interests in exchange for a $9 million Aggregate Capital Contribution in cash and/or equity, with a maximum of 10,933,155 common interests available, of which 1,166,203 (2.34% fully diluted as of August 21, 2024) had already been issued. Why it matters: Most of the consideration is to be funded by Virion selling the 500,000 Ocean shares it already holds, credited at actual sale proceeds and limited to 5% of daily OCEA volume under Rule 144, plus $960,000 already credited. If actual contributions fall short by the April 1, 2025 final contribution date, Ocean may, but need not, top up in cash or shares, and its final ownership percentage is set by what was actually paid.
What changed: Item 3.01 / 7.01. On August 19, 2024 Ocean Biomedical, Inc. received a Nasdaq notice that it is not in compliance with Listing Rule 5250(c)(1) because it has not filed its Form 10-Q for the period ended June 30, 2024. Nasdaq requires a compliance plan no later than September 3, 2024 and, on or before October 14, 2024, the filing of that Form 10-Q together with the still-delinquent Form 10-Q for the quarter ended March 31, 2024 and the Form 10-K for the year ended December 31, 2023. The notice has no immediate effect on listing or trading. Why it matters: Three periodic reports are now overdue at once and share a single October 14, 2024 cure date, so a further slip puts all of them past the deadline together. The company states the delay follows from previously disclosed developments around its FY2023 Form 10-K and that it intends to file as soon as practicable. Registrant is Ocean Biomedical, recorded here under the SPAC ticker AEHA.
What changed: Item 3.01 / 7.01. Ocean Biomedical, Inc. received a Nasdaq notice on May 22, 2024 that it is not in compliance with Listing Rule 5250(c)(1) for failing to file its Form 10-Q for the period ended March 31, 2024, which it had reported late on a Form 12b-25 filed May 14, 2024. Nasdaq requires a compliance plan no later than June 14, 2024 and the delinquent Form 10-Q on or before October 14, 2024. The notice has no immediate effect on listing or trading. A press release was furnished as Exhibit 99.1 on May 30, 2024. Why it matters: The company states the 10-Q delay follows from previously disclosed developments around its FY2023 Form 10-K, so the delinquency compounds an existing reporting failure rather than standing alone. The document contradicts itself in its opening sentence, describing 'its Quarterly Report on Form 10-Q for the period ended December 31, 2023 (the Form 10-K)'. Registrant is the post-combination company Ocean Biomedical, filing under the SPAC ticker AEHA in this record.
What changed: Items 3.01 and 7.01, filed by Ocean Biomedical, Inc. On April 1, 2024 the company filed a Form 12b-25 saying its Form 10-K for the period ended December 31, 2023 would be late, having determined it could not file by the April 1, 2024 due date without unreasonable effort or expense. On April 18, 2024 Nasdaq notified it that it REMAINS in non-compliance with the timely filing requirement of Listing Rule 5250(c)(1). Item 7.01 furnishes an April 24, 2024 press release announcing receipt of the notice. Why it matters: Nasdaq set two new dates: a compliance plan must be submitted no later than June 14, 2024, and the delinquent Form 10-K filed on or before October 14, 2024. This is the second timely-filing notice for this registrant, after the November 22, 2023 notice covering the September 30, 2023 Form 10-Q — so the annual report is now late while the earlier quarterly delinquency's own May 20, 2024 deadline is still running, alongside minimum bid price and MVLS deficiencies.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.